« Back to List
Paradigm Shift of Medicine: from Shallow Medicine to Deep Medicine
Time / Place:
⏱️ 10/8 (Fri.) 18:00-18:25 at Online Track 2
Medicine is a science of uncertainty but art of probability. The same symptoms may result from different diagnosis. The same diagnosis may need different treatment modalities. The same therapeutic maneuver may lead to different prognosis. The uncertainty of diagnosis, therapy and prognosis stems from that we do not understand the etiology and pathogenesis. It also arises from our incomplete enrollment of patient’s data. Take peptic ulcer as an example, stress and acid are considered the etiologic factors until the discovery of H. pylori. We cannot cure peptic ulcer by anxiolytics or acid-reducing agents but we can cure it by 2 weeks of antibiotics. The progress of genomic medicine was assumed to be the key for individual variability in manifeatation of diseases and the solution for precision medicine, especially in the diagnosis and management of malignant neoplasms. However, the gut microbiota, so-called secondary genome, can influence host’s health and disease treatment through bacteria-derived metabolites, immunity and gut-brain axis. Accordingly, investigation of host genomics and microbiomics simultaneously could lead to a better understanding of health and diseases. The big data analysis is mandatory for multiomics research. Therefore, machine learning or artificial intelligence becomes important research tools for precision or smart medicine. Deep phenotyping and deep learning are the root of deep medicine. Compared with current shallow medicine, deep medicine can provide a deeper insight into the etiology and pathogenesis through comprehensive data collection and analyses. Collectively, my planned courses will be “Paradigm shift of medicine: form shallow medicine to deep medicine”. The content will include (a)Evolution of etiology, pathogenesis, diagnosis and treatment of peptic ulcer and gastric cancer. (b)Methologic progress of molecular epidemiology, clinical trial, genomic medicine, microbiomics, big data analyses and artificial intelligence.
- 吳明賢 Ming-Shiang Wu
- National Taiwan University Hospital / Superintendent
Ming-Shiang Wu is the distinguished professor and superintendent in the National Taiwan University Hospital, and President of the Gastroenterological Society of Taiwan.
Professor Wu graduated from the National Taiwan University College of Medicine in 1989, and obtained his PhD from the University’s Graduate Institute of Clinical Medicine in 1998.
After completing his internal medicine residency and gastroenterology training, he was appointed staff physician in the Division of Gastroenterology, National Taiwan University Hospital, in 1995.
He has taught at his alma mater since then, gradually rising in the ranks to his present position, to which he was appointed in 2006. Professor Wu’s main areas of interest are Helicobacter pylori-associated gastroduodenal diseases and gastrointestinal malignancy. Author of more than 450 scientific papers and 3 book chapters, he is the members at the editorial boards of Gut and Gastric Cancer.
He is the recipient of several academic research awards, including the Outstanding Research Award of Taiwan’s National Science Council & Ministry of Science & Technology (three times) and the Emerging Leader Award at the Asia Pacific Digestive Week 2008, for his contributions related to gastric carcinogenesis and the pathogenesis of H. pylori-related diseases.